Li Y, Nielsen BF, Levin SA, Te Velthuis AJW, Grenf. Spatio-temporal modelling of in vitro influenza A virus infection: The impact of defective interfering particles on the type I interferon response. PLoS Comput Biol . 2026 Apr 22;22(4):e1014198
Defective interfering particles (DIPs) are incomplete viral genomes that modulate infection by competing with wild-type viruses and activating the innate immune response. Activation of the immune response leads to the production of cytokines and chemokines, including type I interferon (IFN), which restricts viral growth and may cause cell death. How DIPs interact with type I interferon (IFN) in spatially structured environments remains unclear. Focusing here on influenza A viruses, we developed a spatially explicit, stochastic model of in vitro viral infection that integrates virus and DIP replication, IFN signalling, and alternative dispersal modes. We find that: (1) our model captures the ring-like and patchy plaque morphologies observed experimentally; (2) IFN production peaks at an intermediate DIP ratio, reflecting a trade-off between early immune activation and sufficient co-infection; and (3) even a small fraction of long-range spread by virus and DIPs enables escape from the immune-based containment despite long-range IFN diffusion; this causes stronger antiviral responses but earlier peaks in virus egress at similar levels of cell loss. The model is available as an interactive platform: https://shiny-spatial-infection-app-production.up.railway.app/
See Also:
Latest articles in those days:
- Avian Influenza in Humans: Virology, Transmission, and Clinical Priorities 15 hours ago
- Global influenza epidemiology after 2020: patterns of circulation, epidemic timing and duration, and implications for vaccination strategies 1 days ago
- Coding complete genome of LPAI H16N3 virus from Australia suggests intercontinental movement 2 days ago
- Detection of antibodies to avian influenza virus H5N1 clade 2.3.4.4b in naturally infected cattle for more than a year 2 days ago
- A C-type single-domain antibody with protective efficacy against H1N1 via respiratory administration 2 days ago
[Go Top] [Close Window]


